---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-23-030944"
form_type: "8-K"
ticker: "DYAI"
cik: "0001213809"
company_name: "DYADIC INTERNATIONAL INC"
filed_at: "2023-11-08T23:59:59+00:00"
generated_at: "2026-06-08T08:44:20.324496+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Dyadic Q3 revenue $397K (-55% YoY); cash $8.2M; Phase 1 top-line results expected Dec 2023

## Summary
- Revenue $397K vs $880K YoY; net loss $1.614M ($0.06) vs $1.809M ($0.06).
- Cash $8.2M as of Sep 30, down from $12.7M at Dec 31, 2022.
- Received $0.6M upfront in Oct for Dapibus animal-free dairy enzyme license.
- DYAI-100 Phase 1 top-line results expected Dec 2023; no major safety concerns.
- New collaboration with Mass General/DoD ($5.88M grant) and bYoRNA for mRNA.

## SEC filing metadata
- accession: 0001437749-23-030944
- form_type: 8-K
- ticker: DYAI
- cik: 0001213809
- company_name: DYADIC INTERNATIONAL INC
- filed_at: 2023-11-08T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1213809/000143774923030944/0001437749-23-030944-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1213809/000143774923030944/dyai20230825_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-23-030944
- JSON: https://secwatch.observer/filing/0001437749-23-030944.json
- Plain text: https://secwatch.observer/filing/0001437749-23-030944.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.